Wednesday, July 8, 2026

pharma · Rheumatoid Arthritis · Calcium

Universal Integrated

Universal Corporation is a pharma organization headquartered in HILLSIDE, NJ, CN. Primary therapeutic focus areas include Rheumatoid Arthritis, Calcium, Polycystic Ovary Syndrome, Diabetic Foot, Plaque Psoriasis. NovaPha

HILLSIDE, NJ, CN HQ
2006 Founded
304 Employees
NMPA registrant Type
Company details
Status
Public
HQ
HILLSIDE, NJ, CN
Founded
2006
Employees
304
Programs
89
Drugs
105
Patents
42
Clinical program

autologous FL-33 CAR T therapy

Phase 1 · small molecule · Refractory/Relapsed Acute Myeloid Leukaemia

autologous FL-33 CAR T therapy for Refractory/Relapsed Acute Myeloid Leukaemia is a Phase 1 program (small_molecule) at Universal Integrated with 1 ClinicalTrials.gov record(s).

← All Universal Integrated projects Phase 1 small molecule active

Internal code BJGBYY-IIT-LCYJ-2024-004

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Universal Integrated
Phase
Phase 1
Modality
small_molecule
Indication
Refractory/Relapsed Acute Myeloid Leukaemia
Status
active
Trials
1